Roth Affirms BioLineRx (BLRX( at 'Buy'; Balance Sheet Strong as BL-8040 Momentum Builds
Tweet Send to a Friend
Roth Capital affirms BioLineRx (Nasdaq: BLRX) at Buy with a price target of $7 following Q1 results reported earlier ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
